CHICAGO — In this video, Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about a study in older patients with relapsed/refractory multiple myeloma.
The study was presented at ASCO Annual Meeting and investigated an oral two-drug regimen for frail patients with relapsed refractory disease.
“It’s very interesting that patients can tolerate it well even when they are very frail,” said Fung, chair and professor in the bone marrow transplant and cellular therapies department at Fox Chase Cancer Center.
